Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EF5 to Measure Tumor Hypoxia in NSCLC
NCT00041028Phase 2Completed
- Sponsor
- Duke University
- Start
- May 2002
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ef5 in non-small cell lung cancer (NSCLC), sponsored by Duke University. Primary endpoint: Frequency and degree of hypoxia as measured by EF5 binding. Started May 2002; status: completed.
02
Drugs
ef5
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00041028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041028.